GENETIC · Unmapped registry intervention
iCasp9M28z T cell infusions
Find medicine records ·
Find other trials using this name
Clinical trial
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
NCT02414269
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
cyclophosphamide
Normalized identity: cyclophosphamideView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
pembrolizumab
Normalized identity: pembrolizumabView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedMalignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Malignant Pleural Diseaseunresolved
Mesotheliomaverified · MONDO: mesothelioma
Metastasesunresolved
Lung Cancerverified · MONDO: lung cancer
Breast Cancerverified · MONDO: breast cancer
Interventions
iCasp9M28z T cell infusionsGENETIC
cyclophosphamideDRUG · verified · RxNorm: cyclophosphamide
pembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
Memorial Sloan Kettering Cancer Centerlead sponsor
Bellicum Pharmaceuticalscollaborator
United States Department of Defensecollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02414269 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.